# VolitionRx

Source: https://onco.cc/companies/volitionrx/  
OnCo record `volitionrx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VolitionRx develops low-cost blood tests that measure nucleosomes, the packaging units of DNA released by dying cells, to detect and monitor cancer and sepsis.

## Summary

VolitionRx Limited, listed on NYSE American as VNRX, is an epigenetics diagnostics company with a 20,000 square foot laboratory and manufacturing site in Gembloux (Isnes), Belgium and executive offices in the United States. Its Nucleosomics platform quantifies circulating nucleosomes and their epigenetic modifications in a routine blood sample using immunoassays that run on standard clinical analysers. Products include Nu.Q NETs, a CE-marked assay for NETosis in sepsis being commercialised with Sysmex; Nu.Q Vet Cancer Test, a canine screening test reported to detect 76 percent of systemic cancers at 97 percent specificity; Nu.Q Discover research assays; and the Nu.Q Cancer pipeline, including a Nu.Q Lung Cancer test being prepared for reimbursement submission with Hospices Civils de Lyon.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Henderson, NV
- Type: diagnostics
- Website: https://volition.com/
- Ticker: VNRX

## Notes

- The Q2 2026 release dateline is Henderson, Nevada, not Austin, Texas; the website describes Gembloux, Belgium as the primary operating site. Human cancer tests remain in development; only the veterinary and NETs assays are commercial.

## Sources

- Official website: https://volition.com/
- Investor relations: https://ir.volition.com/
- Q2 2026 results (Aug 2026): https://volition.com/volitionrx-limited-announces-second-quarter-2026-financial-results-and-business-update

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/volitionrx.json